Active Ingredient: Mirikizumab
Mirikizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intravenous, 900 milligrams mirikizumab, once every 4 weeks, 3 doses in total, over the duration of 12 weeks. Afterwards, subcutaneous, 300 milligrams mirikizumab, once every 4 weeks.
The recommended mirikizumab dose regimen has 2 parts.
Induction dose: The induction dose is 900 mg by intravenous infusion for at least 90 minutes at weeks 0, 4 and 8.
Maintenance dose: The maintenance dose is 300 mg by subcutaneous injection every 4 weeks after completion of induction dosing.
Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by week 24.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.